Arrowhead Pharmaceuticals (ARWR) closed at $47.78 on November 13, 2026, up 1.3% from the previous close, on volume of 2,952,486 shares (30-day average 1,897,543).
Data as of November 13, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 29, 2026 | Calendar Call Spread | 20-Nov : 18-Dec-26 60 C | 400 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 12, 2026. See the 10 largest for 30, 60 and 90 days
Analysts Conflicted on These Healthcare Names: ProKidney (PROK) and Arrowhead Pharmaceuticals (ARWR)
TipRanks (Fri, 13-Nov 4:00 PM ET)
RBC Capital Reaffirms Their Buy Rating on Arrowhead Pharmaceuticals (ARWR)
TipRanks (Fri, 13-Nov 11:55 AM ET)
Arrowhead Pharmaceuticals (ARWR) Gets a Buy from UBS
TipRanks (Fri, 13-Nov 9:06 AM ET)
Arrowhead Pharmaceuticals GAAP EPS of -$5.11 misses by $1.51, revenue of $450.82M misses by $13.32M
Seeking Alpha News (Thu, 12-Nov 4:02 PM ET)
Arrowhead Pharmaceuticals Reports 2026 Fiscal Year-End Results
Business Wire (Thu, 12-Nov 4:01 PM ET)
Here are the major earnings after the close Thursday
Seeking Alpha News (Thu, 12-Nov 10:00 AM ET)
TipRanks (Wed, 11-Nov 6:40 AM ET)
TipRanks (Tue, 10-Nov 9:01 AM ET)
Piper Sandler Reaffirms Their Buy Rating on Arrowhead Pharmaceuticals (ARWR)
TipRanks (Tue, 10-Nov 7:56 AM ET)
Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conferences
Business Wire (Mon, 9-Nov 4:00 PM ET)
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
Arrowhead Pharmaceuticals trades on the NASDAQ stock market under the symbol ARWR.
As of November 13, 2026, ARWR stock price climbed to $47.78 with 2,952,486 million shares trading.
ARWR has a beta of 1.72, meaning it tends to be more sensitive to market movements. ARWR has a correlation of 0.16 to the broad based SPY ETF.
ARWR has a market cap of $6.73 billion. This is considered a Mid Cap stock.
Last quarter Arrowhead Pharmaceuticals reported $38 million in Revenue and -$3.01 earnings per share. This fell short of revenue expectation by $-24 million and missed earnings estimates by -$1.49.
In the last 3 years, ARWR traded as high as $95.49 and as low as $9.57.
The top ETF exchange traded funds that ARWR belongs to (by Net Assets): VTI, IJH, VB, VBK, VXF.
ARWR has outperformed the market in the last year with a return of +15.4%, while the SPY ETF gained +11.5%. However, in the most recent history, ARWR shares have underperformed the stock market with its stock returning -45.2% in the last 3 month period and -21.0% for the last 2 week period, while SPY has returned -2.1% and -1.9%, respectively.
ARWR support price is $45.50 and resistance is $48.80 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ARWR shares will trade within this expected range on the day.
